Disease Domain | Count |
---|---|
Neoplasms | 14 |
Endocrinology and Metabolic Disease | 4 |
Hemic and Lymphatic Diseases | 3 |
Immune System Diseases | 3 |
Top 5 Drug Type | Count |
---|---|
CAR-T | 14 |
Target |
Mechanism CD19 inhibitors [+3] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism TSHR modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism MUC1 inhibitors [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Mar 2021 |
Sponsor / Collaborator |
Start Date10 Oct 2020 |
Sponsor / Collaborator Zhejiang University [+1] |
Start Date05 Apr 2017 |
Sponsor / Collaborator Zhejiang University [+1] |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
ICTCAR 023 ( TSHR ) | Thyroid Cancer More | Phase 2 Clinical |
Anti-thyroid stimulating hormone receptor chimeric antigen receptor T cell therapy(Innovative Cellular Therapeutics Co., Ltd.) ( TSHR ) | Thyroid Cancer More | Phase 2 |
dPD-1 hCD19 CART cell therapy(Innovative Cellular Therapeutics Co., Ltd.) ( CD19 x PD-1 ) | Non-Hodgkin Lymphoma More | Phase 2 |
ICT19G1 ( CD19 ) | Acute Lymphoblastic Leukemia More | Phase 1 |
Anti MUC 1 chimeric antigen receptor T cell therapy(Innovative Cellular Therapeutics Co., Ltd.) ( MUC1 ) | Breast Cancer More | Phase 1 |